Glutamic Acid
In clinical developmentAlso known as (2S)-2-Aminopentanedioic acid, (S)-2-Aminopentanedioic acid, (S)-Glutamic acid, Glu+4 more
(2S)-2-Aminopentanedioic acid, (S)-2-Aminopentanedioic acid, (S)-Glutamic acid, Glu, L-Glutamic Acid, L-Glutaminic acid, ácido glutámico, Glutamic-L Acid.
Recent clinical, regulatory, research and industry developments relating to this drug.
Hippocampal-Specific Insulin Resistance Elicits Synaptic Effects on Glutamate Neurotransmission.
Multi-Omic Analysis of Glutamate Excitotoxicity in Primary Neuronal Cultures.
The Glutamate/GABA-Glutamine Cycle: Insights, Updates, and Advances.
Synapse-specific catecholaminergic modulation of neuronal glutamate release.
Gut Microbiome Modulation of Glutamate Dynamics: Implications for Brain Health and Neurotoxicity.
Dendritic, delayed, stochastic CaMKII activation in behavioural time scale plasticity.
Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience8
- International journal of molecular sciences7
- Nature6
- Nature communications4
- Journal of neurochemistry3
- Biomolecules2
- Andersen JV2
- Danbolt NC2
- Feilding A2
- Hutten NRPW2
- Kuypers KPC2
- Mason NL2
- Ramaekers JG2
- Schousboe A2
- School of Medicine3
- University of Copenhagen3
- Institute of Basic Medical Sciences2
- Lawrence Berkeley National Laboratory2
- Maastricht University2
- The Beckley Foundation2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 12 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 6 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 9 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 7 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 7 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 5 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 5 of the same disease areas as Glutamic Acid in the shared literature.
Studied across 3 of the same disease areas as Glutamic Acid in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials